(e,e,e,e)-squalene

(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.

Cross Reference

Introduction

To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with (e,e,e,e)-squalene?

(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Stomach Ulcer D013276 75 associated lipids
Otitis Media D010033 12 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Occupational D009783 12 associated lipids
Pain D010146 64 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lung Neoplasms D008175 171 associated lipids
Inflammation D007249 119 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Coronary Disease D003327 70 associated lipids
Acne Vulgaris D000152 35 associated lipids
Occupational Diseases D009784 42 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Leukemia P388 D007941 43 associated lipids
Metabolism, Inborn Errors D008661 46 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Alzheimer Disease D000544 76 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Fibrosarcoma D005354 8 associated lipids
Arteriosclerosis D001161 86 associated lipids
Leukemia D007938 74 associated lipids
Neuroblastoma D009447 66 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Cholestasis D002779 23 associated lipids
Olfaction Disorders D000857 17 associated lipids
Nervous System Diseases D009422 37 associated lipids
Psoriasis D011565 47 associated lipids
Hyperlipoproteinemia Type II D006938 22 associated lipids
Periodontitis D010518 22 associated lipids
Leukemia, Experimental D007942 42 associated lipids
Hepatitis D006505 11 associated lipids
Cholelithiasis D002769 16 associated lipids
Pregnancy Complications, Infectious D011251 11 associated lipids
Hyperlipidemias D006949 73 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Vitamin E Deficiency D014811 29 associated lipids
Chondrodysplasia Punctata D002806 8 associated lipids
Niemann-Pick Diseases D009542 25 associated lipids
Hyperlipoproteinemia Type III D006952 4 associated lipids
Photosensitivity Disorders D010787 8 associated lipids
Hyperlipoproteinemias D006951 15 associated lipids
Parkinson Disease D010300 53 associated lipids
Celiac Disease D002446 16 associated lipids
Keloid D007627 12 associated lipids
Influenza, Human D007251 11 associated lipids
Leukemia, Hairy Cell D007943 5 associated lipids
Gallbladder Diseases D005705 3 associated lipids
Micronuclei, Chromosome-Defective D048629 33 associated lipids
Xanthomatosis D014973 17 associated lipids
Atherosclerosis D050197 85 associated lipids
Ossification, Heterotopic D009999 2 associated lipids
Fatigue D005221 10 associated lipids
Keratitis, Herpetic D016849 5 associated lipids
Rosacea D012393 13 associated lipids
Parasitemia D018512 5 associated lipids
Lipodystrophy D008060 4 associated lipids
Exostoses, Multiple Hereditary D005097 3 associated lipids
Tinea Versicolor D014010 5 associated lipids
Parvoviridae Infections D010322 4 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Chronic Disease D002908 7 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Coronavirus Infections D018352 4 associated lipids
Viremia D014766 4 associated lipids
Alopecia Areata D000506 6 associated lipids
Scalp Dermatoses D012536 11 associated lipids
Fasciitis D005208 2 associated lipids
Pneumonia, Lipid D011017 2 associated lipids
Persian Gulf Syndrome D018923 1 associated lipids
Steatorrhea D045602 2 associated lipids
Hemorrhagic Septicemia, Viral D031941 1 associated lipids
Per page 10 20 50 100 | Total 84

PubChem Associated disorders and diseases

What pathways are associated with (e,e,e,e)-squalene

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with (e,e,e,e)-squalene?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with (e,e,e,e)-squalene?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with (e,e,e,e)-squalene

Download all related citations
Per page 10 20 50 100 | Total 1766
Authors Title Published Journal PubMed Link
Rasch MR et al. Chains, sheets, and droplets: assemblies of hydrophobic gold nanocrystals with saturated phosphatidylcholine lipid and squalene. 2012 Langmuir pmid:23033891
Singh M et al. MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine. 2012 Hum Vaccin Immunother pmid:22832252
Vesikari T et al. Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age. 2012 Hum Vaccin Immunother pmid:22906943
Della Cioppa G et al. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults. 2012 Hum Vaccin Immunother pmid:22426371
Faenzi E et al. One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies. 2012 Vaccine pmid:22521851
Hatz C et al. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations. 2012 Vaccine pmid:22626675
Hwang SM et al. Comparison of the adverse events associated with MF59-adjuvanted and non-adjuvanted H1N1 vaccines in healthy young male Korean soldiers. 2012 Jpn. J. Infect. Dis. pmid:22627298
Siegrist CA et al. Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine. 2012 Antivir. Ther. (Lond.) pmid:22544169
Yang M et al. MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice. 2012 Int. Immunopharmacol. pmid:22595192
Cabrera-Vique C et al. Bioactive compounds and nutritional significance of virgin argan oil--an edible oil with potential as a functional food. 2012 Nutr. Rev. pmid:22537213
Stella B et al. Nonpolymeric nanoassemblies for ocular administration of acyclovir: pharmacokinetic evaluation in rabbits. 2012 Eur J Pharm Biopharm pmid:22008147
Oral E et al. A new mechanism of oxidation in ultrahigh molecular weight polyethylene caused by squalene absorption. 2012 J. Biomed. Mater. Res. Part B Appl. Biomater. pmid:22190411
Sancho A et al. More on influenza vaccine in young children. 2012 N. Engl. J. Med. pmid:22738111
Yang P et al. Two concise enantioselective total syntheses of (-)-glabrescol implicate alternative biosynthetic pathways starting from squalene. 2012 Org. Lett. pmid:22817611
Ramírez-Torres A et al. Proteomics and gene expression analyses of squalene-supplemented mice identify microsomal thioredoxin domain-containing protein 5 changes associated with hepatic steatosis. 2012 J Proteomics pmid:22796066
Surls J et al. Increased membrane cholesterol in lymphocytes diverts T-cells toward an inflammatory response. 2012 PLoS ONE pmid:22723880
Girod A et al. Composition of fingermark residue: a qualitative and quantitative review. 2012 Forensic Sci. Int. pmid:22727572
Sarpietro MG et al. Squalenoyl prodrug of paclitaxel: synthesis and evaluation of its incorporation in phospholipid bilayers. 2012 Int J Pharm pmid:22728161
Wu S et al. Engineering triterpene metabolism in tobacco. 2012 Planta pmid:22729821
Langley JM et al. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity. 2012 Pediatr. Infect. Dis. J. pmid:22801094
Block SL et al. Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children. 2012 Pediatr. Infect. Dis. J. pmid:22481427
Sémiramoth N et al. Self-assembled squalenoylated penicillin bioconjugates: an original approach for the treatment of intracellular infections. 2012 ACS Nano pmid:22482704
Langley JM et al. Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study. 2012 Vaccine pmid:22469860
Dell'Era L et al. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. 2012 Vaccine pmid:22138210
Allain V et al. Self-assembled nucleolipids: from supramolecular structure to soft nucleic acid and drug delivery devices. 2012 Nucleic Acids Res. pmid:22075995
Garçon N et al. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion. 2012 Expert Rev Vaccines pmid:22380826
Ramírez-Torres A et al. Proteomics and gene expression analyses of mitochondria from squalene-treated apoE-deficient mice identify short-chain specific acyl-CoA dehydrogenase changes associated with fatty liver amelioration. 2012 J Proteomics pmid:22402057
Tronchoni J et al. Lipid composition of wine strains of Saccharomyces kudriavzevii and Saccharomyces cerevisiae grown at low temperature. 2012 Int. J. Food Microbiol. pmid:22405355
Fox CB et al. Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions. 2012 AAPS PharmSciTech pmid:22415641
Nassim C et al. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age. 2012 Pediatr. Infect. Dis. J. pmid:22418661
Fox CB et al. Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines. 2012 Clin. Vaccine Immunol. pmid:22896687
Reynales H et al. A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic. 2012 Vaccine pmid:22902681
Naziri E et al. Recovery of squalene from wine lees using ultrasound assisted extraction-a feasibility study. 2012 J. Agric. Food Chem. pmid:22888984
Dorea JG Safety of thimerosal in vaccines: for whom and how many doses? 2011 Mar-Apr Therapie pmid:23189333
Kozlov VG and Viktorova EG [Evaluation of the efficiency and reactogenicity of emulsion-based adjuvant systems in the manufacture of polyclonal enteroviral diagnostic sera]. 2011 Mar-Apr Vopr. Virusol. pmid:21545042
Durando P et al. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. 2011 Jan-Feb Hum Vaccin pmid:21245655
Schellenberger MT et al. Evaluation of adjuvants for a candidate conjugate vaccine against benzo[a]pyrene. 2011 Jan-Feb Hum Vaccin pmid:21245662
Sarpietro MG et al. Synthesis of n-squalenoyl cytarabine and evaluation of its affinity with phospholipid bilayers and monolayers. 2011 Int J Pharm pmid:21219999
Brasser AJ et al. Presence of wax esters and squalene in human saliva. 2011 Arch. Oral Biol. pmid:21247555
Arguedas A et al. Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. 2011 Hum Vaccin pmid:21285531
Pariani E et al. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. 2011 Vaccine pmid:21974995
Andrews NJ et al. Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. 2011 Vaccine pmid:21875635
Vesikari T et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. 2011 N. Engl. J. Med. pmid:21995388
Oliaro-Bosso S et al. Characterization of the channel constriction allowing the access of the substrate to the active site of yeast oxidosqualene cyclase. 2011 PLoS ONE pmid:21811565
Bildstein L et al. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes. 2011 Eur J Pharm Biopharm pmid:21784150
Della Cioppa G et al. Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. 2011 Vaccine pmid:21906647
Tabache F et al. Acute polyarthritis after influenza A (H1N1) immunization. 2011 Joint Bone Spine pmid:21444232
Sun Y et al. A reproducible in-vivo model of lymphatic malformation in rats. 2011 J. Comp. Pathol. pmid:21419420
Meier S et al. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. 2011 Vaccine pmid:21419775
Réjiba S et al. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. 2011 Nanomedicine pmid:21419876